AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22498663 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral sensory nerve stimulation combined with task-oriented training
Number of subjects: 22
Study 22498663 — intervention group
Group type: COMPARATOR
Intervention: Task-oriented training alone
Number of subjects: 22
Study 22498663 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22
Study 20079168 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scanning with 16 x 1.25 mm collimation and a 70 ml contrast injection
Number of subjects: 40
Study 20079168 — intervention group
Group type: COMPARATOR
Intervention: CT with 64 x 0.625 mm collimation and 20 ml of contrast injection
Number of subjects: 40
Study 17621601 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane 6% for 30 min
Number of subjects: 28
Study 17621601 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane 2% for 30 min
Number of subjects: 28
Study 16306539 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes case management
Number of subjects: 149
Study 16306539 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatment (Control)
Number of subjects: 149
Study 12220942 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol Turbuhaler 6 microg
Number of subjects: 16
Study 12220942 — intervention group
Group type: COMPARATOR
Intervention: Formoterol Aerolizer 12 microg
Number of subjects: 16
Study 9620514 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 20 mg
Number of subjects: 12
Study 9620514 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 2 mg
Number of subjects: 12
Study 9620514 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 10 mg + Alfentanil 1 mg
Number of subjects: 12
Study 9620514 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 2.5 mg + Alfentanil 0.25 mg
Number of subjects: 12
Study 9620514 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 5 mg
Number of subjects: 12
Study 9620514 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 0.5 mg
Number of subjects: 12
Study 7695320 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin once daily
Number of subjects: 10
Study 7695320 — intervention group
Group type: COMPARATOR
Intervention: Amikacin twice daily
Number of subjects: 10
Study 2785234 — intervention group
Group type: EXPERIMENTAL
Intervention: multidose cardioplegia
Number of subjects: 20
Study 2785234 — intervention group
Group type: COMPARATOR
Intervention: single-dose cardioplegia with a cooling jacket
Number of subjects: 20
Study 562092 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (5 mg)
Number of subjects: 210
Study 562092 — intervention group
Group type: COMPARATOR
Intervention: Diphenidol (40 mg)
Number of subjects: 210
Study 562092 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 ml of 0.9% saline)
Number of subjects: 210
Study 31947813 — intervention group
Group type: EXPERIMENTAL
Intervention: Both-parent migration
Number of subjects: 0
Study 31155692 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 134
Study 31155692 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 134
Study 31155692 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 134
Study 26377300 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab maintenance treatment (300 mg followed by 1000 mg 1 week later and every 8 weeks for up to 2 years)
Number of subjects: 474
Study 26377300 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 474
Study 26377300 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab maintenance treatment
Number of subjects: 474
Study 23860722 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 3041
Study 23860722 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 3041
Study 23860722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3041
Study 21306322 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with intrathecal morphine (SA)
Number of subjects: 162
Study 21306322 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 162
Study 19254583 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue steroid group (betamethasone, 2 12‐mg doses 24 hours apart)
Number of subjects: 437
Study 19254583 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 437
Study 16778261 — intervention group
Group type: EXPERIMENTAL
Intervention: Training by a housestaff team
Number of subjects: 49
Study 16778261 — intervention group
Group type: COMPARATOR
Intervention: Training by a single experienced teaching attending
Number of subjects: 49
Study 16778261 — intervention group
Group type: EXPERIMENTAL
Intervention: Scenario-based simulation training (SST)
Number of subjects: 49
Study 15046541 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 0
Study 15046541 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 0
Study 15046541 — intervention group
Group type: COMPARATOR
Intervention: Citalopram (active comparator for escitalopram)
Number of subjects: 0
Study 15046541 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (active comparator for duloxetine)
Number of subjects: 0
Study 15046541 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine (active comparator for duloxetine)
Number of subjects: 0
Study 11932134 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Couples Therapy (BCT)
Number of subjects: 80
Study 11932134 — intervention group
Group type: COMPARATOR
Intervention: Individual-based treatment (IBT)
Number of subjects: 80
Study 9614604 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition curriculum
Number of subjects: 596
Study 9614604 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard curriculum
Number of subjects: 596
Study 9614604 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice condition
Number of subjects: 596
Study 9614604 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendance in either curriculum
Number of subjects: 596
Study 9614604 — intervention group
Group type: COMPARATOR
Intervention: No choice condition
Number of subjects: 596
Study 7649691 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented PCA modular cruciform‐stemmed tibial components
Number of subjects: 26
Study 7649691 — intervention group
Group type: COMPARATOR
Intervention: Uncemented PCA modular cruciform‐stemmed tibial components
Number of subjects: 26
Study 2798991 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepines (BZ)
Number of subjects: 5
Study 2798991 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepines (BZ) plus Levodropropizine
Number of subjects: 5
Study 2798991 — intervention group
Group type: COMPARATOR
Intervention: Levodropropizine
Number of subjects: 5
Study 29441 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam (1 mg)
Number of subjects: 117
Study 29441 — intervention group
Group type: COMPARATOR
Intervention: Nitrazepam (5 mg)
Number of subjects: 117
Study 29441 — intervention group
Group type: COMPARATOR
Intervention: Placebo (one tablet)
Number of subjects: 117
Study 31147486 — intervention group
Group type: EXPERIMENTAL
Intervention: The Reading House (TRH)
Number of subjects: 278
Study 31147486 — intervention group
Group type: COMPARATOR
Intervention: Get Ready to Read! (GRTR)
Number of subjects: 278
Study 31147486 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent, child, and provider impressions of TRH
Number of subjects: 278
Study 28466022 — intervention group
Group type: EXPERIMENTAL
Intervention: In-plane injection
Number of subjects: 46
Study 28466022 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-of-plane injection
Number of subjects: 46
Study 27004917 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen 3g infusion
Number of subjects: 412
Study 27004917 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 412
Study 25073431 — intervention group
Group type: EXPERIMENTAL
Intervention: ECT
Number of subjects: 60
Study 25073431 — intervention group
Group type: EXPERIMENTAL
Intervention: ECT + AET
Number of subjects: 60
Study 25073431 — intervention group
Group type: EXPERIMENTAL
Intervention: AET
Number of subjects: 60
Study 22206074 — intervention group
Group type: EXPERIMENTAL
Intervention: Galvanic zinc-copper complex
Number of subjects: 124
Study 22206074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 19712040 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-virus H5N1 clade 1 A/Vietnam vaccine (2-dose priming regimen)
Number of subjects: 141
Study 19712040 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5-microg dose of a clade 2.1 A/Indonesia vaccine (booster)
Number of subjects: 141
Study 17513402 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-linolenate (GLA) 890 mg/d (5 g/d borage oil)
Number of subjects: 50
Study 17513402 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (5 g/d)
Number of subjects: 50
Study 17513402 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-linolenate (GLA)
Number of subjects: 50
Study 17513402 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (Control)
Number of subjects: 50
Study 17513402 — intervention group
Group type: EXPERIMENTAL
Intervention: GLA-GLA (subgroup continued GLA)
Number of subjects: 50
Study 17513402 — intervention group
Group type: COMPARATOR
Intervention: Control-GLA (subgroup crossed over to GLA)
Number of subjects: 50
Study 14701773 — intervention group
Group type: EXPERIMENTAL
Intervention: PS‐341 1.5 mg/m(2) administered intravenously twice weekly for 2 weeks every 21 days, with dose escalation to 1.7 mg/m(2) in absence of grade 3 to 4 toxicities.
Number of subjects: 23
Study 14701773 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified.
Number of subjects: 23
Study 11181998 — intervention group
Group type: EXPERIMENTAL
Intervention: vinorelbine/cisplatin
Number of subjects: 612
Study 11181998 — intervention group
Group type: COMPARATOR
Intervention: vindesine/cisplatin
Number of subjects: 612
Study 11181998 — intervention group
Group type: COMPARATOR
Intervention: vinorelbine alone
Number of subjects: 612
Study 9441058 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month short-course chemotherapy regimen (SCC) with rifampicin, isoniazid and pyrazinamide for 2 months followed by rifampicin with isoniazid for another 4 months (6R series)
Number of subjects: 193
Study 9441058 — intervention group
Group type: COMPARATOR
Intervention: 12-month standard regimen of ethambutol and isoniazid with streptomycin supplemented for 2 weeks (12E series)
Number of subjects: 193
Study 7951290 — intervention group
Group type: EXPERIMENTAL
Intervention: Contract-relax treatment
Number of subjects: 75
Study 7951290 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg pull treatment
Number of subjects: 75
Study 7951290 — intervention group
Group type: COMPARATOR
Intervention: Control group (supine quietly for 5 minutes)
Number of subjects: 75
Study 3108930 — intervention group
Group type: EXPERIMENTAL
Intervention: L-deprenyl 10 mg/day
Number of subjects: 17
Study 3108930 — intervention group
Group type: EXPERIMENTAL
Intervention: L-deprenyl 40 mg/day
Number of subjects: 17
Study 3108930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 29966958 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental heat wrap therapy
Number of subjects: 176
Study 29966958 — intervention group
Group type: COMPARATOR
Intervention: Multimodal treatment without supplemental heat wrap therapy
Number of subjects: 176
Study 27052212 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical medication review followed by a pharmaceutical care plan
Number of subjects: 512
Study 27052212 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 512
Study 24513614 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermogenic nutritional supplement
Number of subjects: 21
Study 24513614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 22088165 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home interdisciplinary care management intervention combining palliative care and geriatric medicine approaches.
Number of subjects: 80
Study 22088165 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified.
Number of subjects: 80
Study 20736149 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc
Number of subjects: 721
Study 20736149 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 721
Study 18416470 — intervention group
Group type: EXPERIMENTAL
Intervention: lafutidine 10 mg
Number of subjects: 10
Study 18416470 — intervention group
Group type: COMPARATOR
Intervention: LPZ 30 mg
Number of subjects: 10
Study 15641907 — intervention group
Group type: EXPERIMENTAL
Intervention: Inference learning
Number of subjects: 0
Study 15641907 — intervention group
Group type: COMPARATOR
Intervention: Classification learning
Number of subjects: 0
Study 12777162 — intervention group
Group type: EXPERIMENTAL
Intervention: Neptune Krill Oil (NKO)
Number of subjects: 70
Study 12777162 — intervention group
Group type: COMPARATOR
Intervention: omega‐3 fish oil
Number of subjects: 70
Study 11383262 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling
Number of subjects: 118
Study 11383262 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 118
Study 11383262 — intervention group
Group type: COMPARATOR
Intervention: Splint therapy
Number of subjects: 118
Study 11383262 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal adjustment therapy
Number of subjects: 118
Study 11383262 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of splint and occlusal adjustment therapy
Number of subjects: 118
Study 8878139 — intervention group
Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids (BCAA)
Number of subjects: 7
Study 8878139 — intervention group
Group type: COMPARATOR
Intervention: Flavored water (placebo)
Number of subjects: 7
Study 8878139 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA
Number of subjects: 7
Study 8878139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 1283584 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil or Enalapril
Number of subjects: 27
Study 1283584 — intervention group
Group type: COMPARATOR
Intervention: Atrial pacing
Number of subjects: 27
Study 1283584 — intervention group
Group type: COMPARATOR
Intervention: Dipyridamole infusion
Number of subjects: 27
Study 3862151 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine 30 mg, p.o.
Number of subjects: 8
Study 3862151 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 8
Study 30009752 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Care Skills Training Workshops (CCSTW)
Number of subjects: 64
Study 30009752 — intervention group
Group type: COMPARATOR
Intervention: Psycho-educational programme
Number of subjects: 64
Study 26036190 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) with aspirin
Number of subjects: 139
Study 26036190 — intervention group
Group type: COMPARATOR
Intervention: Aspirin only
Number of subjects: 139
Study 26323997 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa 60 μg/week
Number of subjects: 50
Study 26323997 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa 120 μg/week
Number of subjects: 50
Study 26323997 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa 240 μg/week
Number of subjects: 50
Study 23922479 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise sedation (group Cs)
Number of subjects: 86
Study 23922479 — intervention group
Group type: COMPARATOR
Intervention: Continuous sedation (group Cc)
Number of subjects: 86
Study 23922479 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise sedation (group Ns)
Number of subjects: 86
Study 23922479 — intervention group
Group type: COMPARATOR
Intervention: Continuous sedation (group Nc)
Number of subjects: 86
Study 21383847 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber right hand placed beside the real hand
Number of subjects: 0
Study 21383847 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire data and physiological evidence from skin conductance responses
Number of subjects: 0
Study 21383847 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditions for elicitation of the supernumerary hand illusion
Number of subjects: 0
Study 21383847 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison with traditional rubber hand illusion
Number of subjects: 0
Study 21383847 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial hand's effect on multisensory processes
Number of subjects: 0
Study 18771838 — intervention group
Group type: EXPERIMENTAL
Intervention: One-visit root canal treatment
Number of subjects: 121
Study 18771838 — intervention group
Group type: COMPARATOR
Intervention: Two-visit root canal treatment
Number of subjects: 121
Study 16303215 — intervention group
Group type: EXPERIMENTAL
Intervention: Single nasal dose of vaccine containing 15, 30, or 45 microg of each of the three HA antigens
Number of subjects: 78
Study 16303215 — intervention group
Group type: EXPERIMENTAL
Intervention: Two nasal doses containing 30 microg of each HA, separated by 2 weeks
Number of subjects: 78
Study 16303215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 16303215 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine (all doses)
Number of subjects: 78
Study 14998054 — intervention group
Group type: EXPERIMENTAL
Intervention: Ear acupuncture points (EAP) detection during orthopedic surgery
Number of subjects: 25
Study 14998054 — intervention group
Group type: COMPARATOR
Intervention: Ear acupuncture points (EAP) detection in patients
Number of subjects: 25
Study 10957689 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive hypertension care program; details on dosage and duration not available.
Number of subjects: 0
Study 8836865 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg alternate day oral aspirin (regular formulation)
Number of subjects: 22
Study 8836865 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg alternate day oral aspirin (enteric coated formulation)
Number of subjects: 22
Study 8836865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 1445490 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol (250 mg/day)
Number of subjects: 26
Study 1445490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 3918688 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg daily
Number of subjects: 66
Study 3918688 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 30 mg daily
Number of subjects: 66
Study 3918688 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg daily (in smokers)
Number of subjects: 66
Study 3918688 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 30 mg daily (in smokers)
Number of subjects: 66
Study 31504974 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief, one-on-one, telephone-adapted mindfulness-based stress reduction (MBSR) intervention, 3 sessions
Number of subjects: 70
Study 31504974 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 70
Study 30099318 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath-focused practice
Number of subjects: 0
Study 30099318 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement-focused practice
Number of subjects: 0
Study 30099318 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 27592123 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU+MBCT-S (n=82)
Number of subjects: 164
Study 27592123 — intervention group
Group type: COMPARATOR
Intervention: TAU (n=82)
Number of subjects: 164
Study 24548425 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous rFeIFN‐ω (Virbagen® omega, Virbac, Carros, France) administered via eight injections over four months.
Number of subjects: 26
Study 24548425 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rFeIFN‐ω administered daily.
Number of subjects: 26
Study 24548425 — intervention group
Group type: COMPARATOR
Intervention: Control group (subcutaneous rFeIFN‐ω).
Number of subjects: 26
Study 21436164 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate (3 mg intravenous single dose)
Number of subjects: 20
Study 21436164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 19473824 — intervention group
Group type: COMPARATOR
Intervention: CHO-Meal (control-meal plus 45 g carbohydrates)
Number of subjects: 11
Study 19473824 — intervention group
Group type: COMPARATOR
Intervention: PRO-Meal (control-meal plus 45 g of casein)
Number of subjects: 11
Study 19473824 — intervention group
Group type: COMPARATOR
Intervention: CHO+PRO-Meal (PRO-meal plus 45 g carbohydrates)
Number of subjects: 11
Study 19473824 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO-Meal (control-meal plus 45 g carbohydrates) with casein added
Number of subjects: 11
Study 19473824 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO+CHO-Meal (PRO-meal plus 45 g carbohydrates)
Number of subjects: 11
Study 17357131 — intervention group
Group type: EXPERIMENTAL
Intervention: Parkinson's disease patients
Number of subjects: 101
Study 17357131 — intervention group
Group type: COMPARATOR
Intervention: Control patients
Number of subjects: 101
Study 15572275 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (0.5 mg)
Number of subjects: 45
Study 15572275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 12233993 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine-dependent outpatients (treatment group)
Number of subjects: 188
Study 12233993 — intervention group
Group type: COMPARATOR
Intervention: Cocaine-dependent outpatients (female participants)
Number of subjects: 188
Study 12233993 — intervention group
Group type: COMPARATOR
Intervention: Cocaine-dependent outpatients (male participants)
Number of subjects: 188
Study 10087080 — intervention group
Group type: EXPERIMENTAL
Intervention: P3f component identified in faster responders
Number of subjects: 10
Study 10087080 — intervention group
Group type: EXPERIMENTAL
Intervention: P3b component identified
Number of subjects: 10
Study 10087080 — intervention group
Group type: EXPERIMENTAL
Intervention: Pmp component identified
Number of subjects: 10
Study 10087080 — intervention group
Group type: EXPERIMENTAL
Intervention: Pnt component associated with left frontocentral nontarget positivity
Number of subjects: 10